Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Niguldipine
- Development stage
- Discontinued
- Lead developer
- Eli Lilly
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
01
Overview
Niguldipine is a calcium channel blocker with α1-adrenergic antagonist properties. It was investigated by Eli Lilly and Company for the treatment of hypertension but was discontinued.
- Other names
- NiguldipinoNiguldipinum
02
Targets
LTCC (Voltage-gated calcium channel (L-type))ADRA1B (α1B)ADRA1A (α1A)
Beyond the preview
Go deeper on Niguldipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Niguldipine.